Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).
about
Contemporary assessment and pharmacotherapy of Tourette syndromeTourette syndrome and obsessive-compulsive disorderDrug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trialsPharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug responseInvestigating the Additive Interaction of QT-Prolonging Drugs in Older People Using Claims Data.Summary of information on human CYP enzymes: human P450 metabolism data.Assessing QT interval prolongation and its associated risks with antipsychotics.Macrolide drug interactions: an update.Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycinRisk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.Pimozide (Orap) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current in native cardiac myocytes.Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.The significance of QT interval in drug development.Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics.Antimicrobial-associated QT interval prolongation: pointes of interest.Incidence of Sustained Ventricular Tachycardia in Patients with Prolonged QTc After the Administration of Azithromycin: A Retrospective Study.Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs.Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations.Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen.Electrophysiologic, pharmacokinetic, and pharmacodynamic values indicating a higher risk of torsades de pointes.Drug-induced QT-interval prolongation: considerations for clinicians.Antipsychotic drug toxicology in children.Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?RHB-104 triple antibiotics combination in culture is bactericidal and should be effective for treatment of Crohn's disease associated with Mycobacterium paratuberculosis.How to Choose In Vitro Systems to Predict In Vivo Drug Clearance: A System Pharmacology Perspective.Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy.Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature.Review of epidemiology, clinical presentation, diagnosis, and treatment of common primary psychiatric causes of cutaneous disease.
P2860
Q24607941-3054BA48-CE58-4751-A83F-419211373B6DQ24657240-0892FB5A-D2F6-492F-BEB0-A0D3A3CB0CD3Q28071256-0777C002-65B0-4FE4-8E20-6B07E8635CA1Q28252209-4AE47C06-C14F-47D0-8841-5CA118859BC3Q31145263-942A1EAA-6A80-4029-9A5F-F6DCD513D6CCQ32103802-9582DAB3-B8A7-48C2-A7C8-459E755EA143Q33160123-FE5799B1-77E5-4DB5-9057-DAE2767DF624Q33895235-9F5CD473-F5E2-4B5C-BEC9-B107EF514DD9Q34049823-7267FA1B-8F8A-4A02-8335-7121AD5CACD7Q34186776-51DF1B83-7C0D-40CA-B46E-DEEA3F4E5A7BQ34381754-526A2C81-C89C-45D9-BA1C-292ED3F49201Q34518083-9348E1DE-DFF9-4188-A2D9-3E0D4DA92EDCQ34633457-3711A120-FB69-406F-90E2-9627EC737E70Q34808276-ACD3A525-2E75-4430-A1CE-D5488DFEE58CQ36048792-709B53C7-FB75-4D7B-9C8C-0A8A37DF8C5CQ36655034-5D5BD91C-C3B8-48DE-AFA6-14268E3E49D5Q36761496-B1B69871-1FD2-475B-8950-B14AEBD187D5Q36871056-241774D5-4BB4-4466-AA3C-E2D760717956Q37344782-BC4561E5-06CD-4F80-A700-6A1BC50D0479Q37435948-D3D541AA-D4AE-4FB8-A67A-3C723FE63EC5Q37765087-DAA37941-0763-46AF-A118-9626BAE4842AQ37767425-EA9403AE-C9F8-4334-944C-707455DCDD01Q37852719-5AF72F71-D651-4D39-9F03-43894590976AQ38958223-AE7ECC1C-78E4-4376-A12B-FF2D64012E5DQ39679682-C62E5201-3EF1-4739-8489-FADCED055075Q40353496-6488FA28-DC33-4A76-B50C-A5F803B95295Q46721837-1C42325C-9377-4148-BD6A-63ADF9F9124EQ47118928-95928205-1D11-47B7-B18D-B65B82E19F11Q48156893-45D9AB6F-8865-4D0F-A869-437682E1D0C5
P2860
Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Effect of clarithromycin on th ...... cytochrome P450 2D6 (CYP2D6).
@ast
Effect of clarithromycin on th ...... cytochrome P450 2D6 (CYP2D6).
@en
Effect of clarithromycin on th ...... olizers of cytochrome P450 2D6
@nl
type
label
Effect of clarithromycin on th ...... cytochrome P450 2D6 (CYP2D6).
@ast
Effect of clarithromycin on th ...... cytochrome P450 2D6 (CYP2D6).
@en
Effect of clarithromycin on th ...... olizers of cytochrome P450 2D6
@nl
prefLabel
Effect of clarithromycin on th ...... cytochrome P450 2D6 (CYP2D6).
@ast
Effect of clarithromycin on th ...... cytochrome P450 2D6 (CYP2D6).
@en
Effect of clarithromycin on th ...... olizers of cytochrome P450 2D6
@nl
P2093
P1476
Effect of clarithromycin on th ...... cytochrome P450 2D6 (CYP2D6).
@en
P2093
P356
10.1016/S0009-9236(99)70117-7
P407
P577
1999-01-01T00:00:00Z